What is your preferred approach to third-line treatment of metastatic HER2 positive esophageal adenocarcinoma after progression on FOLFOX/CAPOX + trastuzumab, then T-DXd?  

PD-L1 CPS of 1, no other actionable mutations except HER2.



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at NYU Long Island School of Medicine
I agree with Dr. @Hochster regarding the meri...
Sign in or Register to read more